J+D Forecasting, a number one supplier of forecasting options for the pharmaceutical business, is worked up to formally share the information of our acquisition by Consider, a distinguished member of the Norstella household. This monumental improvement, disclosed on January 10, 2024, marks a major chapter in our firm’s journey.

Within the midst of the dynamic pharmaceutical panorama, characterised by legislative modifications, regulatory shifts, geopolitical challenges, and patent expiries, the flexibility to navigate uncertainties with precision is significant. Recognizing the strategic significance of correct market forecasting, J+D Forecasting is thrilled to affix forces with Consider.

The amalgamation of Consider’s world-class consensus forecasting and consulting experience, mixed with J+D Forecasting’s specialised fashions and software program delivered by means of modern cloud-based administration and analytical options, guarantees to raise our capabilities. This partnership will empower our shoppers with much more clever and constant insights, fostering efficient collaboration throughout the pharmaceutical business.

David James, CEO and Founding father of J+D Forecasting, expressed his optimism, saying, “The necessity for high-quality forecasting within the pharmaceutical and biotech house has by no means been greater. Bringing collectively two of probably the most revered forecasting suppliers within the business supplies huge alternatives for our prospects. I’m trying ahead to collaborating with the Consider group and Norstella to carry modern options to the market.”

As we embark on this thrilling journey as a part of the Norstella household, J+D Forecasting stays devoted to delivering cutting-edge forecasting options that may proceed to form the way forward for the pharmaceutical business.

Mike Gallup, CEO, Norstella mentioned: “We’re delighted to welcome the J+D Forecasting group to the Norstella household. Their experience in growing bespoke forecasting fashions and modern, intuitive options will present our prospects with a good wider breadth of experience and cutting-edge perception. The addition of those capabilities considerably boosts our means to assist obtain our mission of smoothing the trail of life-saving therapies from pipeline to affected person.”

About Consider

Since 1996, Consider, a Norstella firm, has offered the life sciences business with the information, perception and intelligence to facilitate assured determination making on high-value investments in therapies and markets. We allow our shoppers to embed our proprietary and business knowledge into their workflows, instruments and processes to allow them to work extra successfully and effectively. For extra details about Consider, go to www.consider.com

About Norstella

Norstella consists of a number of distinguished pharmaceutical options suppliers—Citeline, Consider, MMIT, Panalgo, and The Dedham Group. United by a shared mission, to clean the trail to life-saving therapies for sufferers and suppliers. Norstella gives complete insights all through the drug improvement lifecycle, leveraging unparalleled knowledge, cutting-edge know-how, and skilled insights and consultancy. For extra info, go to Norstella.com

About J+D Forecasting

J+D work alongside Pharmaceutical Forecasters, Analysts, Enterprise Insights Managers and Advertising and marketing Departments to ship cloud-based forecast options and create efficient forecast fashions throughout a product lifecycle, that meet the wants of all inner stakeholders, from World and Regional groups by means of to particular person associates. They steadiness market complexity with modern, but straightforward to make use of know-how, underpinned with the most effective pharmaceutical forecasting rules.

Shoppers’ wants are central to the companies and options the create – they create options with particular enterprise wants in thoughts. With their data, expertise and fervour for innovation, they encourage confidence in pharmaceutical funding choices and form the market alongside their shoppers. Study extra at jdforecasting.com